Completed PHASE2 INTERVENTIONAL 2-arm NCT05579899

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

A Randomized, Vehicle-controlled, Safety and Efficacy Study of EVO101 in Adult Subjects With Atopic Dermatitis

Sponsor: Evommune, Inc.

Interventions EVO101

Updated 7 times since 2022 Last updated: Feb 27, 2025 Started: Sep 27, 2022 Primary completion: Jul 27, 2023 Completion: Jul 27, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Atopic Dermatitis Eczema, this trial is completed. The trial is conducted by Evommune, Inc. and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Apr 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jul 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Dec 2022 — Jul 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2

First recorded

Sep 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Evommune, Inc.

Data source: Evommune, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , College Station, United States , Coral Gables, United States , Encinitas, United States , Fayetteville, United States , High Point, United States , Houston, United States , Indianapolis, United States , Las Vegas, United States , Los Angeles, United States and 10 more locations